Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of ANRO is 31 and suggests 38% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell